|
Owens & Minor, Inc. (OMI): Modelo de Negócios Canvas [Jan-2025 Atualizado] |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Owens & Minor, Inc. (OMI) Bundle
Na intrincada paisagem do gerenciamento da cadeia de suprimentos de saúde, Owens & Minor, Inc. (OMI) surge como uma potência estratégica, transformando como os suprimentos médicos navegam de fabricantes para profissionais de saúde. Seu inovador modelo de negócios Canvas revela um complexo ecossistema de parcerias, tecnologias e serviços que revolucionam a distribuição médica, oferecendo sistemas de saúde eficiência e custo-efetividade sem precedentes. Ao integrar perfeitamente a logística avançada, a tecnologia de ponta e as soluções abrangentes da cadeia de suprimentos, a OMI fica na vanguarda da logística da saúde, criando valor por meio de um modelo de negócios meticulosamente criado que aborda os desafios críticos da indústria.
Owens & Minor, Inc. (OMI) - Modelo de Negócios: Principais Parcerias
Fabricantes de produtos e fornecedores de produtos de saúde
Owens & Menor mantém parcerias estratégicas com mais de 1.200 fabricantes de produtos médicos. Os principais fabricantes incluem:
| Fabricante | Foco em parceria | Categorias de produtos |
|---|---|---|
| Cardinal Health | Distribuição de suprimentos médicos | Suprimentos cirúrgicos, EP |
| Medline Industries | Distribuição de equipamentos médicos | Consumíveis hospitalares |
Organizações de compras em grupo (GPOs)
Owens & Menores colabora com vários GPOs para otimizar estratégias de compras:
- Premier Healthcare Alliance
- Vizient, Inc.
- Grupo de compra da HealthTrust
Sistemas hospitalares e profissionais de saúde
Parcerias diretas incluem:
| Sistema de Saúde | Número de instalações servidas | Valor anual do contrato |
|---|---|---|
| HCA Healthcare | 180 hospitais | US $ 325 milhões |
| Saúde da Ascensão | 140 hospitais | US $ 275 milhões |
Parceiros de Serviço de Tecnologia e Logística
- SAP for Enterprise Resource Planning
- Manhattan Associados para gerenciamento da cadeia de suprimentos
- FedEx para logística e distribuição
Dispositivos médicos e empresas farmacêuticas
| Empresa | Tipo de parceria | Volume de distribuição |
|---|---|---|
| Johnson & Johnson | Distribuição exclusiva | US $ 412 milhões anualmente |
| Becton Dickinson | Gestão da cadeia de abastecimento | US $ 287 milhões anualmente |
Owens & Minor, Inc. (OMI) - Modelo de negócios: Atividades -chave
Distribuição de suprimentos médicos e logística
Owens & Menor processou US $ 11,2 bilhões em receita anual para 2022, com 98% derivados da distribuição de suprimentos médicos. A empresa opera 14 centros de distribuição nos Estados Unidos, cobrindo aproximadamente 2,5 milhões de pés quadrados de espaço logístico.
| Métrica de distribuição | Dados quantitativos |
|---|---|
| Volume anual de distribuição | 300 milhões de produtos médicos/cirúrgicos |
| Locais do centro de distribuição | 14 instalações estratégicas |
| Cobertura de logística | 50 estados dos EUA e vários territórios |
Gerenciamento e compras de inventário
A empresa mantém um sofisticado sistema de gerenciamento de inventário com recursos de rastreamento em tempo real.
- Taxa de rotatividade de estoque: 8,2 vezes por ano
- Valor médio de retenção de inventário: US $ 425 milhões
- Taxa de eficiência de compras: 99,7%
Otimização da cadeia de suprimentos de assistência médica
Owens & Menores atende a aproximadamente 6.000 prestadores de serviços de saúde, incluindo hospitais, centros de cirurgia ambulatorial e locais de atendimento alternativo.
| Métrica da cadeia de suprimentos | Dados de desempenho |
|---|---|
| Clientes de prestadores de serviços de saúde | Mais de 6.000 instituições |
| Velocidade de atendimento de pedidos | 98,5% da mesma entrega/no dia seguinte |
| Investimento em tecnologia da cadeia de suprimentos | US $ 47 milhões em 2022 |
Fornecimento de produtos médicos e compras
Owens & Menores fontes de produtos de mais de 1.200 fabricantes em todo o mundo, com foco em suprimentos médicos e cirúrgicos.
- Número de relacionamentos do fabricante: 1.200+
- Categorias de produtos fornecidas: mais de 200.000 SKUs exclusivos
- Cobertura internacional de fornecimento: 35 países
Serviços de integração de tecnologia de saúde
A empresa investiu US $ 62 milhões em iniciativas de infraestrutura de tecnologia e transformação digital em 2022.
| Métrica de integração de tecnologia | Dados quantitativos |
|---|---|
| Investimento em tecnologia | US $ 62 milhões em 2022 |
| Usuários da plataforma digital | 4.500+ Instituições de Saúde |
| Alocação de P&D de tecnologia | 3,2% da receita anual |
Owens & Minor, Inc. (OMI) - Modelo de negócios: Recursos -chave
Extensa rede de distribuição
A partir de 2024, Owens & Menor opera 11 centros de distribuição nacional nos Estados Unidos, cobrindo aproximadamente 2,5 milhões de pés quadrados de espaço de armazém. A empresa serve 6.000 prestadores de serviços de saúde com uma rede de distribuição abrangente.
| Locais do centro de distribuição | Mágua quadrada total | Capacidade anual de distribuição |
|---|---|---|
| Centros de distribuição nacionais | 2,5 milhões de pés quadrados | Mais de 500 milhões de produtos médicos anualmente |
Infraestrutura avançada de armazenamento e logística
A empresa investiu US $ 42,3 milhões em tecnologia de logística Em 2023, com os principais recursos de infraestrutura, incluindo:
- Sistemas de gerenciamento de inventário automatizado
- Tecnologias de rastreamento em tempo real
- Instalações de armazenamento controlado por temperatura
- Sistemas avançados de atendimento de pedidos
Fortes relacionamentos com prestadores de serviços de saúde
Owens & Menor mantém parcerias com 6.300+ instalações de saúde, incluindo:
| Tipo de provedor | Número de parcerias |
|---|---|
| Hospitais | 3,200+ |
| Centros de cirurgia ambulatorial | 1,500+ |
| Clínicas | 1,600+ |
Tecnologia de gerenciamento de cadeia de suprimentos proprietária
Investimentos de tecnologia em 2023 totalizaram US $ 18,7 milhões, focando em:
- Análise preditiva orientada a IA
- Gerenciamento de inventário baseado em nuvem
- Sistemas de rastreamento habilitados para blockchain
Força de trabalho qualificada com experiência no setor de saúde
A partir de 2024, Owens & Menores empregos 4.800 profissionais com uma experiência média do setor de 8,6 anos.
| Categoria de funcionários | Número de funcionários | Experiência média |
|---|---|---|
| Especialistas em cadeia de suprimentos | 1,200 | 9,2 anos |
| Profissionais de tecnologia | 650 | 7,5 anos |
| Vendas e gerenciamento de contas | 1,100 | 8,9 anos |
Owens & Minor, Inc. (OMI) - Modelo de Negócios: Proposições de Valor
Soluções abrangentes de fornecimento médico e cirúrgico
Owens & Menor fornece soluções de fornecimento médico e cirúrgico com o seguinte portfólio de produtos:
| Categoria de produto | Contribuição anual da receita | Quota de mercado |
|---|---|---|
| Suprimentos cirúrgicos | US $ 2,1 bilhões | 15.7% |
| Consumíveis médicos | US $ 1,8 bilhão | 12.4% |
| Equipamento de proteção pessoal | US $ 890 milhões | 8.3% |
Gerenciamento de cadeia de suprimentos econômico
Métricas de eficiência da cadeia de suprimentos:
- Taxa de rotatividade de estoque: 12,5x
- Redução de custos operacionais: 6,2% anualmente
- Economia de otimização de logística: US $ 127 milhões
Distribuição de produtos confiável e eficiente
Recursos de rede de distribuição:
| Métrica de distribuição | Desempenho |
|---|---|
| Centros de distribuição nacionais | 12 |
| Taxa de atendimento de pedidos | 99.4% |
| Tempo médio de entrega | 1,7 dias |
Serviços simplificados de compras de saúde
Ofertas de serviço de compras:
- Contratos de organização de compras em grupo: 3.200+
- Clientes da Instalação de Saúde: 6.500
- Volume anual de transação de compras: US $ 10,3 bilhões
Suporte de cadeia de suprimentos médicos de ponta a ponta
Recursos de suporte da cadeia de suprimentos:
| Serviço de suporte | Valor anual |
|---|---|
| Gerenciamento de fornecedores | US $ 750 milhões |
| Integração de tecnologia | US $ 220 milhões |
| Serviços de consultoria | US $ 180 milhões |
Owens & Minor, Inc. (OMI) - Modelo de Negócios: Relacionamentos do Cliente
Parcerias contratuais de longo prazo
A partir de 2024, Owens & Menor mantém aproximadamente 150 contratos de distribuição de saúde a longo prazo com hospitais, sistemas de saúde e organizações de compras em grupo.
| Tipo de contrato | Número de contratos | Duração média do contrato |
|---|---|---|
| Sistemas hospitalares | 87 | 3-5 anos |
| Organizações de compras em grupo | 42 | 4-6 anos |
| Provedores de assistência médica especializados | 21 | 2-4 anos |
Gerenciamento de conta dedicado
Owens & A menor emprega 275 gerentes de conta dedicados que atendem a clientes de saúde nos Estados Unidos.
- O gerente médio de contas lida com 12 a 15 clientes de saúde simultaneamente
- Equipes de conta especializadas para diferentes segmentos de saúde
- Reuniões trimestrais de revisão de desempenho com clientes -chave
Plataformas de suporte ao cliente digital
A infraestrutura de suporte digital inclui:
| Plataforma | Usuários ativos mensais | Disponibilidade de serviço |
|---|---|---|
| Portal de clientes on -line | 4.200 instalações de saúde | 24/7 |
| Aplicativo de gerenciamento de pedidos móveis | 2.800 usuários | 24/7 |
| Suporte ao cliente Chatbot | 3.500 interações mensais | Suporte automatizado |
Soluções personalizadas da cadeia de suprimentos
As soluções personalizadas da cadeia de suprimentos desenvolvidas para 68 perfis exclusivos de clientes de saúde em 2024.
- Estratégias de otimização de inventário
- Gerenciamento de suprimentos médicos just-in-time
- Previsão de demanda preditiva
Consultoria de otimização de desempenho contínua
Serviços de consultoria de desempenho fornecidos a 112 organizações de saúde em 2024.
| Serviço de consultoria | Número de clientes | Duração média do engajamento |
|---|---|---|
| Eficiência da cadeia de suprimentos | 62 clientes | 6-9 meses |
| Estratégias de redução de custos | 35 clientes | 3-6 meses |
| Integração de tecnologia | 15 clientes | 9-12 meses |
Owens & Minor, Inc. (OMI) - Modelo de Negócios: Canais
Equipe de vendas diretas
A partir de 2024, Owens & Menor mantém uma força de vendas direta dedicada de aproximadamente 750 profissionais de vendas. A equipe abrange canais de distribuição de assistência médica nos Estados Unidos.
| Métricas de canal de vendas | 2024 dados |
|---|---|
| Total de representantes de vendas | 750 |
| Vendas anuais médias por representante | US $ 3,2 milhões |
| Cobertura geográfica | 50 estados dos EUA |
Plataformas de compras on -line
Owens & Menor opera vários canais de compras digitais com as seguintes especificações:
- Volume da transação da plataforma digital: US $ 1,5 bilhão anualmente
- Taxa de penetração de pedidos on -line: 62% da base total de clientes
- Transações digitais mensais médias: 85.000
Sistemas de pedidos eletrônicos
A infraestrutura de pedidos eletrônicos da empresa inclui:
| Métricas de sistema eletrônico | 2024 Performance |
|---|---|
| Usuários da plataforma eletrônica B2B | 8.500 instalações de saúde |
| Rastreamento de inventário em tempo real | 99,7% de precisão |
| Velocidade de processamento de pedidos | Abaixo de 4 horas |
Feiras de saúde e conferências
Owens & Menor participa de principais eventos de distribuição de saúde:
- Aparições anuais da feira: 18
- Investimentos totais de conferência: US $ 2,3 milhões
- Novas aquisições de clientes por meio de eventos: 127 Provedores de Saúde
Redes de parceria estratégica
O ecossistema de parceria estratégica da empresa inclui:
| Categoria de parceria | Número de parceiros | Impacto anual da receita |
|---|---|---|
| Parcerias do fabricante | 425 | US $ 1,7 bilhão |
| Redes de prestadores de serviços de saúde | 3,200 | US $ 2,4 bilhões |
| Parceiros de integração de tecnologia | 52 | US $ 380 milhões |
Owens & Minor, Inc. (OMI) - Modelo de negócios: segmentos de clientes
Hospitais e sistemas de saúde
A partir de 2023, Owens & Menores atende a aproximadamente 4.000 hospitais de cuidados agudos em todo o país. Esses sistemas de saúde representam 62% da receita total da Companhia, com um valor estimado de compra anual de US $ 3,2 bilhões.
| Métricas de segmento hospitalar | Valor |
|---|---|
| Hospitais totais servidos | 4,000 |
| Contribuição da receita | 62% |
| Valor anual de compras | US $ 3,2 bilhões |
Centros cirúrgicos ambulatoriais
Owens & Menores suporta 6.500 centros cirúrgicos ambulatoriais, representando 18% de sua base de clientes com um valor estimado de compras anuais de US $ 890 milhões.
- Total de Centros Cirúrgicos Ambulatoriais servidos: 6.500
- Contribuição da receita: 18%
- Valor anual de compras: US $ 890 milhões
Práticas médicas
A empresa atende a aproximadamente 75.000 práticas médicas, representando 12% da receita total com um valor anual de compras de US $ 580 milhões.
| Métricas de segmento de prática médica | Valor |
|---|---|
| Total de práticas médicas servidas | 75,000 |
| Contribuição da receita | 12% |
| Valor anual de compras | US $ 580 milhões |
Lares de idosos e instalações de cuidados de longo prazo
Owens & Menores apoia 3.200 casas de repouso e instalações de cuidados de longo prazo, contribuindo com 5% da receita com um valor anual de compras de US $ 240 milhões.
- Total de Instalações de Cuidados de Longo Prazo atendidos: 3.200
- Contribuição da receita: 5%
- Valor anual de compras: US $ 240 milhões
Fabricantes de dispositivos farmacêuticos e médicos
A empresa colabora com 250 fabricantes de dispositivos farmacêuticos e médicos, gerando 3% da receita com um valor anual de compras de US $ 145 milhões.
| Métricas de segmento do fabricante | Valor |
|---|---|
| Total de fabricantes servidos | 250 |
| Contribuição da receita | 3% |
| Valor anual de compras | US $ 145 milhões |
Owens & Minor, Inc. (OMI) - Modelo de negócios: estrutura de custos
Despesas de armazenamento e logística
A partir do ano fiscal de 2023, Owens & Menor relatou despesas totais de armazenamento e logística de US $ 324,7 milhões. A empresa opera vários centros de distribuição nos Estados Unidos.
| Categoria de despesa | Custo anual ($ m) |
|---|---|
| Manutenção das instalações do armazém | 87.3 |
| Equipamento de armazenamento | 42.6 |
| Trabalho do armazém | 129.5 |
| Sistemas de gerenciamento de inventário | 65.3 |
Investimentos de infraestrutura de tecnologia
Em 2023, Owens & Menor investiu US $ 78,2 milhões em infraestrutura tecnológica.
- Desenvolvimento da plataforma digital: US $ 35,6 milhões
- Aprimoramentos de segurança cibernética: US $ 22,4 milhões
- Soluções de computação em nuvem: US $ 20,2 milhões
Custos de pessoal e força de trabalho
As despesas totais de pessoal para 2023 foram de US $ 512,9 milhões.
| Categoria de custo de pessoal | Custo anual ($ m) |
|---|---|
| Salários da base | 342.6 |
| Benefícios | 103.5 |
| Treinamento e desenvolvimento | 28.9 |
| Recrutamento | 37.9 |
Despesas de transporte e distribuição
Os custos de transporte para 2023 totalizaram US $ 276,4 milhões.
- Custos operacionais da frota de caminhões: US $ 156,7 milhões
- Despesas de combustível: US $ 82,3 milhões
- Parcerias de logística de terceiros: US $ 37,4 milhões
Gerenciamento de inventário Sobrecarga
Os custos de gerenciamento de estoque para 2023 foram de US $ 215,6 milhões.
| Despesas de gerenciamento de inventário | Custo anual ($ m) |
|---|---|
| Sistemas de rastreamento de inventário | 43.2 |
| Custos de transporte de estoque | 112.5 |
| Software de inventário | 59.9 |
Owens & Minor, Inc. (OMI) - Modelo de negócios: fluxos de receita
Taxas de distribuição de suprimentos médicos e cirúrgicos
Em 2023, Owens & Menor relatou receita líquida total de US $ 10,5 bilhões. A distribuição de suprimentos médicos e cirúrgicos representou o fluxo de receita primária, representando aproximadamente 85% da receita total.
| Categoria de receita | 2023 quantidade | Porcentagem da receita total |
|---|---|---|
| Distribuição de suprimentos médicos | US $ 8,925 bilhões | 85% |
Cobranças de serviço de logística e compras
Os serviços de logística e compras geraram aproximadamente US $ 1,05 bilhão em receita para 2023, representando 10% da receita total da empresa.
- Taxas de serviço de armazenamento
- Cobranças de logística de transporte
- Serviços de Gerenciamento de Inventário
Receitas de serviço de integração de tecnologia
Os serviços de tecnologia contribuíram com US $ 315 milhões em 2023, representando 3% da receita total.
| Tipo de serviço de tecnologia | 2023 Receita |
|---|---|
| Soluções da cadeia de suprimentos digitais | US $ 210 milhões |
| Integração de tecnologia da saúde | US $ 105 milhões |
Consultoria de otimização da cadeia de suprimentos
Os serviços de consultoria da cadeia de suprimentos geraram US $ 105 milhões em receita para 2023.
Serviços de saúde de valor agregado
Os serviços de valor agregado contribuíram com US $ 105 milhões para a receita da empresa em 2023.
| Categoria de serviço | 2023 Receita |
|---|---|
| Serviços de apoio clínico | US $ 63 milhões |
| Análise de saúde | US $ 42 milhões |
Owens & Minor, Inc. (OMI) - Canvas Business Model: Value Propositions
You're looking at the core value Owens & Minor, Inc. (OMI) is delivering now that they've committed to being a pure-play home-based care company following the sale of their Products & Healthcare Services segment. This focus is designed to create a cleaner investment thesis and better serve patients with chronic conditions at home.
Comprehensive home-based care for chronic conditions
Owens & Minor, Inc. (OMI) is centering its value proposition on supporting patients with chronic conditions directly in their homes. This focus is supported by the financial structure of the company as of late 2025, with continuing operations-primarily the Patient Direct segment-projected to generate full-year 2025 revenue between $2.76 billion and $2.82 billion.
The Patient Direct segment is specifically targeting high-growth therapy categories within home health. For example, in the first quarter of 2025, this segment saw strong performance led by diabetes and sleep supplies.
- Patient Direct Q1 2025 Revenue: $674 million.
- Patient Direct Q1 2025 Adjusted EBITDA: nearly $98 million.
- The segment delivered mid-single-digit top-line growth in Q1 2025.
Direct delivery of essential medical supplies to the patient's home
A key value is the reliable, direct-to-patient delivery of essential medical equipment and supplies. This capability is crucial for managing conditions that require ongoing support, such as diabetes management and sleep apnea therapy.
The company's commitment to this direct model is reflected in its financial segmentation; in the first quarter of 2025, the Patient Direct segment accounted for 25.6% of total revenue, up from 24.4% in 2024, showing the increasing weight of this direct-to-patient value stream.
| Metric | Q3 2025 Continuing Operations | Full Year 2025 Guidance (Projected) |
| Revenue | $697.3 million (Q3 only) | $2.76 billion to $2.82 billion |
| Adjusted EBITDA | $92.2 million (Q3 only) | $376 million to $382 million |
Simplified patient experience for complex therapy management
Owens & Minor, Inc. (OMI) aims to make managing complex therapies easier for the patient. This involves streamlining ordering processes and ensuring consistent access to necessary supplies. The company is focusing investments on technology and automation to improve the patient experience.
The focus on operational improvements is expected to translate directly into profitability for the core business. For the full year 2025, the Patient Direct focus is expected to yield an Adjusted EBITDA between $376 million and $382 million.
The value proposition includes supporting specific patient needs:
- Consistent access to disposable medical supplies.
- Easy ordering processes.
- Reliable delivery services.
Scale and reliability in the fragmented home healthcare market
The scale of Owens & Minor, Inc. (OMI)'s Patient Direct platform provides reliability in a fragmented market. The company is a significant player, serving customers across a wide geographical footprint. This scale is a foundation for leading in the evolving home-based care market.
The company serves customers in 46 states through its Patient Direct business within the United States. This nationwide reach is a tangible asset supporting their reliability claim. Furthermore, the CEO referenced a recently announced nationwide preferred provider partnership agreement as an example of this growth focus.
Operational excellence through supply chain efficiency
Operational excellence is driven by leveraging technology to optimize the supply chain, which in turn helps reduce the cost to serve patients. A key element here is the partnership with Google Cloud to enhance QSight, a cloud-based clinical inventory management system.
This technology is designed to improve real-time visibility and predictive capabilities within their complex supply chains. Historically, Owens & Minor, Inc. (OMI) has been recognized for this capability, having been placed as No. 1 in Gartner's Top 25 Healthcare Supply Chain organizations based on criteria including network visibility and dynamic supply. This commitment to efficiency is defintely key to their future margin performance.
For Q2 2025, the adjusted operating margin for continuing operations increased to 8.34% from 7.99% in Q2 2024 (non-GAAP), showing tangible progress in operational discipline.
Owens & Minor, Inc. (OMI) - Canvas Business Model: Customer Relationships
You're looking at a company that has made a massive strategic pivot, so the customer relationships are now almost entirely centered on the home-based care patient, which they call the Patient Direct platform. This is where the sticky, long-term value is now concentrated, especially as they finalize the sale of their Products & Healthcare Services segment.
Direct, high-touch patient support and education
The high-touch element comes through specialized digital tools designed for chronic care management. For instance, the ByramConnect digital health platform, powered by the Welldoc App, is a key relationship driver. This isn't just a portal; it's an FDA-cleared class II software as a medical device (SaMD) intended for use by both adult patients with type 1 or type 2 diabetes and their care teams. The platform integrates data from connected sources like fitness trackers, continuous glucose monitors (CGMs), and blood pressure monitors, giving care teams a holistic view. This level of integration is what keeps the relationship strong.
Dedicated account management for institutional providers
While the primary focus has shifted, the legacy of serving institutional providers remains relevant in the context of their continuing operations and recent strategic moves. Before the full divestiture, their institutional relationships were supported by solutions like QSight®, a cloud-based clinical inventory management system. This system was being enhanced through a partnership with Google Cloud's Vertex AI to help hospitals and health systems optimize the management of thousands of medical-grade supplies. This shows a history of dedicated, complex service delivery to large entities, even if the current focus is elsewhere.
Automated reorder and resupply programs for chronic care
For patients managing long-term conditions, automation is crucial for adherence and convenience. The Patient Direct segment, which includes brands like Byram, is built around delivering disposable medical supplies directly to patients and home health agencies. This requires robust, automated resupply logistics, which is a core competency they are doubling down on. The strategic acquisition of Rotech was specifically intended to strengthen offerings in areas like respiratory, sleep apnea, diabetes, and wound care, all of which rely heavily on consistent, automated resupply.
Patient-centric digital engagement platforms
The digital platforms are designed to deliver actionable insights directly to the patient and their provider. The ByramConnect platform offers reporting & insights with actionable data based on the patient's unique patterns. Clinical studies on the app showed tangible results for diabetes patients, including reduced A1C, lower blood pressure, and lower body weight. This focus on measurable outcomes is central to the patient-centric relationship model. It's about helping members achieve concrete goals, not just shipping supplies.
Long-term, defintely sticky relationships due to chronic needs
The very nature of serving patients with chronic conditions creates inherent stickiness. These aren't one-time purchases; they are ongoing needs for supplies and support. The Patient Direct segment's performance reflects this focus, showing mid-single-digit top-line growth in 2024 and a mid-teen expansion in EBITDA for Q1 2025. You can see the financial commitment to this segment, as it accounted for 25.6% of total revenue in Q1 2025, an increase from 24.4% in 2024. The full-year 2025 revenue projection for these continuing operations is set between $2.76 billion and $2.82 billion. However, you should note the risk: management disclosed the potential loss of a significant customer contract in 2026, which highlights the competitive pressure even in these sticky relationships.
Here's a quick look at the financial commitment to the core customer relationship segment as of the latest reporting:
| Metric | Value/Range (As of Late 2025 Data) | Period/Context |
| Projected 2025 Revenue (Patient Direct) | $2.76 billion to $2.82 billion | Full Year 2025 Guidance (Continuing Operations) |
| Projected 2025 Adjusted EBITDA (Patient Direct) | $376 million to $382 million | Full Year 2025 Guidance (Continuing Operations) |
| Revenue Contribution (Patient Direct) | 25.6% | Q1 2025 |
| EBITDA Expansion | Mid-teen expansion | Q1 2025 (Patient Direct Segment) |
| YTD Revenue (Continuing Operations) | Nearly $2.1 billion | As of Q3 2025 |
| Q3 2025 Revenue (Continuing Operations) | $697.3 million | Q3 2025 |
The company is clearly unifying its capital deployment and execution around this platform. Finance: draft 13-week cash view by Friday.
Owens & Minor, Inc. (OMI) - Canvas Business Model: Channels
You're looking at how Owens & Minor, Inc. (OMI) gets its core Patient Direct value proposition to the end user as of late 2025, following its strategic pivot away from the Products & Healthcare Services (P&HS) segment.
The Channels block for Owens & Minor, Inc. (OMI) is now almost entirely focused on the Patient Direct segment, which is projected to generate between $2.76 billion and $2.82 billion in revenue for the full year 2025. This segment has scaled significantly since its foundation, growing from approximately $450 million in annual revenue in 2017.
The primary channels for reaching patients and securing service delivery involve a mix of direct logistics and strong institutional partnerships.
Direct-to-patient home delivery network
The home delivery network is the physical manifestation of the Patient Direct strategy, utilizing the footprint established through acquisitions like Apria. This channel is designed to deliver disposable medical supplies directly to patients managing chronic conditions at home. The segment's operational strength is supported by investments in advanced distribution centers, such as the one in West Virginia, which opened in 2025 with advanced automation and robotics technology. The segment's projected Adjusted EBITDA for 2025 is between $376 million and $382 million.
Online and phone-based patient ordering systems
Digital and telephonic ordering capabilities are critical for managing the volume of home-based care. For instance, the Byram brand within the Patient Direct segment achieved record collections in the first quarter of 2025 due to enhanced revenue cycle efforts, which implies effective utilization of these ordering systems. The segment's overall Q2 2025 revenue from continuing operations was $681.9 million.
Referral networks from physicians and hospital systems
Securing referrals is a major upstream channel for the Patient Direct business. A key element here is the new national provider agreement with Optum Health, which Owens & Minor, Inc. (OMI) is actively scaling. This agreement provides a preferred position within the Optum closed network for the Apria and Byram brands. The company's strategy involves leveraging this network to capture patient volume.
Field-based clinical and sales support teams
The sales and clinical support teams are the human interface for driving and maintaining these referral channels. The Patient Direct segment deploys a significant field force to engage potential referral sources.
- The company has 450 forward-facing salespeople marketing directly to over 100,000 potential referral sources within the Optum network alone.
- Owens & Minor, Inc. (OMI) is a Fortune 500 company powered by more than 20,000 teammates worldwide.
- The addition of sales staff contributed to double-digit growth in several smaller Patient Direct categories during 2024.
Here's a quick look at the scale of the core channel segment as of the 2025 projections:
| Metric | Value (FY 2025 Projection/Data) | Source Period |
|---|---|---|
| Patient Direct Projected Revenue | $2.76 billion to $2.82 billion | FY 2025 Guidance |
| Patient Direct Projected Adjusted EBITDA | $376 million to $382 million | FY 2025 Guidance |
| Patient Direct Q2 2025 Revenue (Continuing Ops) | $681.9 million | Q2 2025 |
| Optum Referral Sources Targeted | Over 100,000 | Late 2025 |
| Forward-Facing Salespeople (Optum Focus) | 450 | Late 2025 |
If onboarding for new patients takes 14+ days, churn risk rises, which is a near-term operational risk for this direct channel.
Owens & Minor, Inc. (OMI) - Canvas Business Model: Customer Segments
Owens & Minor, Inc. is actively reshaping its customer base to focus almost entirely on the Patient Direct segment, which serves home-based care needs, following the definitive agreement to sell the Products & Healthcare Services (P&HS) segment.
The continuing operations, which represent the core Patient Direct business, are heavily oriented toward individuals managing long-term health needs. This segment has shown increasing importance to the overall revenue profile.
| Customer/Segment Group | 2024 Revenue Share (Approximate) | Q1 2025 Revenue Share (Continuing Ops) | 2025 Full Year Revenue Guidance (Continuing Ops) |
| Patient Direct Segment (Focus) | ~24.4% | 25.6% | $2.76 billion to $2.82 billion |
| Products & Healthcare Services (Divested/Discontinued) | ~74% | N/A (Classified as discontinued) | N/A (Sale in progress/completed) |
Patients with chronic conditions are the primary end-users served by the Patient Direct platform, which includes brands like Apria and Byram.
- Sleep therapy saw revenue growth in the high single-digit rate in Q1 2025 after the sleep journey initiative.
- Wound/Ostomy/Urology (WOU) categories delivered double-digit growth in Q1 2025.
- The business is focused on chronic conditions such as diabetes and sleep apnea.
- Oxygen therapy growth stabilized in Q1 2025, with expectations for further recovery throughout 2025.
Commercial payors and Medicare Advantage plans represent a critical layer of the Patient Direct customer base, as they are the entities responsible for reimbursement for the home medical equipment (HME) and services provided to beneficiaries.
The company is leveraging its scale to secure favorable arrangements, evidenced by a recently announced nationwide preferred provider partnership agreement with Optum. The Patient Direct segment's Adjusted EBITDA for Q1 2025 was $98 million, reflecting margin expansion to 14.5%. The full-year 2025 Adjusted EBITDA guidance for continuing operations is $376 million to $382 million.
Home Health Agencies and institutional providers were historically served by the P&HS segment, which primarily served hospitals and clinics. With the sale of P&HS, the focus shifts. Home Health Agencies are now more likely viewed as referral sources or partners within the home-based care ecosystem.
- The planned acquisition of Rotech, Inc. (announced July 2024, expected to close in the first half of 2025) is intended to strengthen Patient Direct product offerings across respiratory, sleep apnea, diabetes, and wound care, expanding access to the durable medical equipment market.
- The overall home healthcare market, which Owens & Minor, Inc. is targeting, is valued at $459 billion in 2025.
Government programs, specifically Medicare and Medicaid beneficiaries, form a significant portion of the patient population utilizing HME and chronic condition management services. The company is focused on navigating potential changes in government policy, including tariffs. Restricted cash as of September 30, 2024, included amounts held in escrow related to the Centers for Medicare & Medicaid Services (CMS) Bundled Payments for Care Improvement (BPCI) initiatives.
Finance: review 2026 leverage target of below 3x by year-end, tied to divestiture proceeds.
Owens & Minor, Inc. (OMI) - Canvas Business Model: Cost Structure
You're looking at the cost side of the Owens & Minor, Inc. (OMI) business as they aggressively pivot to a pure-play Patient Direct model following the P&HS segment divestiture. The cost structure reflects significant one-time transition expenses alongside the ongoing operational costs of the remaining business.
The core operating costs for the continuing operations, which primarily represent the Patient Direct segment, show the baseline expense profile. We can map the key components using the nine months ended September 30, 2025, figures, which gives a good year-to-date view.
| Cost Component (9 Months Ended 9/30/2025) | Amount (in thousands) | Context/Notes |
| Cost of net revenue (product and patient service equipment) | $1,087,024 | Represents the direct cost to generate revenue from continuing operations. |
| Selling, General, and Administrative (SG&A) expenses | $796,061 | This figure shows a slight decrease year-over-year for the nine-month period. |
| Interest expense, net | $79,252 | Actual net interest expense for the first nine months of 2025. |
The interest expense component is definitely a focus area given the debt load, which stood at $2.1 billion as of September 30, 2025, partly due to transaction expenses. While the actual nine-month net interest expense was $79,252 thousand, you were tracking the projection for the pre-divestiture structure, which was estimated to be in the range of $138 million to $142 million annually.
The transition away from the Products & Healthcare Services (P&HS) segment introduces specific, non-recurring costs that heavily impacted the GAAP results, especially in Q2 2025.
- Transaction breakage fee of $80 million paid in Q2 2025 related to the terminated Rotech acquisition.
- This $80,000 thousand fee was recognized in Q2 2025 and is included in the nine-month figures for continuing operations.
- Transaction financing fees, net, for the nine months ended September 30, 2025, totaled $18,288 thousand.
Stranded costs are the ongoing overhead expenses from the divested P&HS segment that Owens & Minor, Inc. (OMI) must absorb temporarily until they are fully eliminated or absorbed by the leaner structure. These costs are a direct drag on the pure-play focus.
Here's what we know about those stranded costs:
- Year-to-date stranded costs through September 30, 2025, totaled $25 million.
- The stranded cost for the third quarter alone was $11 million.
- Management continues to believe the annualized run-rate for these stranded costs will be approximately $40 million.
To give you a snapshot of the immediate impact of the P&HS classification on the income statement for Q3 2025, the Loss from discontinued operations, net of tax, was a significant $(144,669 thousand), which is separate from the ongoing operating costs of the Patient Direct business.
Owens & Minor, Inc. (OMI) - Canvas Business Model: Revenue Streams
The revenue streams for Owens & Minor, Inc. (OMI) are now sharply focused on the continuing operations of the Patient Direct segment, following the announced divestiture of the Products & Healthcare Services segment. This focus means revenue generation is centered on supporting home-based care for patients with chronic conditions.
The financial expectations for this pure-play Patient Direct business for the full 2025 fiscal year are clearly defined by management guidance.
- Net revenue from continuing operations (Patient Direct) is guided to be between $2.76B to $2.82B for 2025.
- Adjusted EBITDA for continuing operations is projected to fall in the range of $376M to $382M for 2025.
Year-to-date performance as of the third quarter of 2025 shows the segment is tracking toward these goals, with revenue reaching nearly $2.1 billion, representing a 3.4% increase from the prior year period. Year-to-date adjusted EBITDA was $285 million, up 6.3% from $268 million last year.
The core of the revenue collection process involves reimbursement arrangements with various third-party payors. This is where the majority of the top-line dollars are realized.
| Revenue Component | 2025 Full Year Guidance (Patient Direct) | Year-to-Date 2025 Actual (Continuing Operations) |
| Net Revenue | $2.76B to $2.82B | Nearly $2.1 billion |
| Adjusted EBITDA | $376M to $382M | $285 million |
The sources of payment for the services and products provided by the Patient Direct segment are segmented by the entity responsible for the payment.
- Reimbursement from Commercial Payors constitutes the majority of the revenue base.
- Revenue is also collected via reimbursement from Medicare and Medicaid programs.
- Direct sales contribute revenue through the delivery of home medical equipment and disposable supplies to patients and home health agencies.
Growth in specific product categories supports this revenue, with management noting strong year-over-year growth in sleep therapy, ostomy, and urology categories in the third quarter of 2025.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.